Maastricht, The Netherlands, 11th May 2020 – Cristal Therapeutics, a Phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces the publication of a paper on its CriPec® nanomedicine technology in the high-impact journal Small.
The research1, reports the results of a collaboration between Cristal Therapeutics and Mainz and RWTH Aachen Universities, Germany. Current understanding indicates that when nanoparticles are introduced into a living organism, they rapidly adsorb proteins to form a corona, which thereafter determines their fate in the body. This research however shows that when CriPec® nanoparticles are exposed to plasma, they form a negligible protein corona.
This is a significant result. It demonstrates that the superior biological properties of CriPec® nanoparticles, such as prolonged circulation and improved pharmacokinetics, are due to rational design rather than patient-related factors. This also explains the inter-patient invariability in pharmacokinetics observed for CriPec® technology in the clinic, which is the basis for the improved tumour targeting and therapeutic profile of CriPec® nanomedicines.
Dr Cristianne Rijcken, CSO of Cristal Therapeutics said: “This elegant study demonstrates that the superior biological profiles of our CriPec® nanoparticles are the result of optimal pharmaceutical composition, not interaction with biological compounds after administration. On this understanding, we are able to rationally design CriPec® nanomedicines targeting specific indications. Combined with our straightforward manufacturing process, this creates multiple new product opportunities.”
References
- Alberg, I. et al. Polymeric nanoparticles with neglectable protein corona. Small. https://doi.org/10.1002/smll.201907574 (2020).
– ENDS –
About Cristal Therapeutics
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company’s product candidates are based on its proprietary CriPec® polymeric nanoparticle technology platform, which enables the design of customized nanomedicines with superior therapeutic profiles. CriPec®-based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment.
The Company’s lead product, CPC634, is currently in clinical phase 2. The Company has several other programmes in preclinical development, partially with partners, focussed on the treatment of cancer and other diseases.
Cristal Therapeutics is a private company that has raised over €20M equity financing to date. The Company’s headquarters and laboratories are located in Maastricht, the Netherlands.
Find out more: www.cristaltherapeutics.com
For more information, please contact:
Cristal Therapeutics:
Dr Axel Mescheder
Chief Executive Officer / Chief Medical Officer
T: +49 17 263 608 90
E: Axel.Mescheder@cristaltherapeutics.com
Media relations
Instinctif Partners
Melanie Toyne-Sewell / Dr Katie Duffell
T: +44 20 7457 2013
E: cristal@instinctif.com
